232 related articles for article (PubMed ID: 32596207)
21. Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.
Carbo M; Brandi V; Pascarella G; Staid DS; Colotti G; Polticelli F; Ilari A; Morea V
Int J Mol Med; 2019 Dec; 44(6):2223-2233. PubMed ID: 31638189
[TBL] [Abstract][Full Text] [Related]
22. Multiple discrete soluble aggregates influence polyglutamine toxicity in a Huntington's disease model system.
Xi W; Wang X; Laue TM; Denis CL
Sci Rep; 2016 Oct; 6():34916. PubMed ID: 27721444
[TBL] [Abstract][Full Text] [Related]
23. Dynamic recruitment of ubiquitin to mutant huntingtin inclusion bodies.
Juenemann K; Jansen AHP; van Riel L; Merkx R; Mulder MPC; An H; Statsyuk A; Kirstein J; Ovaa H; Reits EA
Sci Rep; 2018 Jan; 8(1):1405. PubMed ID: 29362455
[TBL] [Abstract][Full Text] [Related]
24. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.
Zeng Y; Guo W; Xu G; Wang Q; Feng L; Long S; Liang F; Huang Y; Lu X; Li S; Zhou J; Burgunder JM; Pang J; Pei Z
Drug Des Devel Ther; 2016; 10():1443-51. PubMed ID: 27110099
[TBL] [Abstract][Full Text] [Related]
25. Polyglutamine- and temperature-dependent conformational rigidity in mutant huntingtin revealed by immunoassays and circular dichroism spectroscopy.
Fodale V; Kegulian NC; Verani M; Cariulo C; Azzollini L; Petricca L; Daldin M; Boggio R; Padova A; Kuhn R; Pacifici R; Macdonald D; Schoenfeld RC; Park H; Isas JM; Langen R; Weiss A; Caricasole A
PLoS One; 2014; 9(12):e112262. PubMed ID: 25464275
[TBL] [Abstract][Full Text] [Related]
26. Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates.
Fukui H; Moraes CT
Hum Mol Genet; 2007 Apr; 16(7):783-97. PubMed ID: 17356014
[TBL] [Abstract][Full Text] [Related]
27. Huntingtin and its role in neuronal degeneration.
Li SH; Li XJ
Neuroscientist; 2004 Oct; 10(5):467-75. PubMed ID: 15359012
[TBL] [Abstract][Full Text] [Related]
28. Juvenile Huntington's Disease Skin Fibroblasts Respond with Elevated Parkin Level and Increased Proteasome Activity as a Potential Mechanism to Counterbalance the Pathological Consequences of Mutant Huntingtin Protein.
Aladdin A; Király R; Boto P; Regdon Z; Tar K
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31717806
[TBL] [Abstract][Full Text] [Related]
29. Compartment-Dependent Degradation of Mutant Huntingtin Accounts for Its Preferential Accumulation in Neuronal Processes.
Zhao T; Hong Y; Li S; Li XJ
J Neurosci; 2016 Aug; 36(32):8317-28. PubMed ID: 27511006
[TBL] [Abstract][Full Text] [Related]
30. SUMO-modifying Huntington's disease.
Soares ES; Prediger RD; Brocardo PS; Cimarosti HI
IBRO Neurosci Rep; 2022 Jun; 12():203-209. PubMed ID: 35746980
[TBL] [Abstract][Full Text] [Related]
31. Degradation of misfolded proteins by autophagy: is it a strategy for Huntington's disease treatment?
Lin F; Qin ZH
J Huntingtons Dis; 2013; 2(2):149-57. PubMed ID: 25063512
[TBL] [Abstract][Full Text] [Related]
32. HSP90 recognizes the N-terminus of huntingtin involved in regulation of huntingtin aggregation by USP19.
He WT; Xue W; Gao YG; Hong JY; Yue HW; Jiang LL; Hu HY
Sci Rep; 2017 Nov; 7(1):14797. PubMed ID: 29093475
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic advances in neural regeneration for Huntington's disease.
D'Egidio F; Castelli V; Lombardozzi G; Ammannito F; Cimini A; d'Angelo M
Neural Regen Res; 2024 Sep; 19(9):1991-1997. PubMed ID: 38227527
[TBL] [Abstract][Full Text] [Related]
34. Transcriptional profiles for distinct aggregation states of mutant Huntingtin exon 1 protein unmask new Huntington's disease pathways.
Moily NS; Ormsby AR; Stojilovic A; Ramdzan YM; Diesch J; Hannan RD; Zajac MS; Hannan AJ; Oshlack A; Hatters DM
Mol Cell Neurosci; 2017 Sep; 83():103-112. PubMed ID: 28743452
[TBL] [Abstract][Full Text] [Related]
35. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
[TBL] [Abstract][Full Text] [Related]
36. Proteostasis of Huntingtin in Health and Disease.
Koyuncu S; Fatima A; Gutierrez-Garcia R; Vilchez D
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28753941
[TBL] [Abstract][Full Text] [Related]
37. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
Chiang MC; Chen HM; Lai HL; Chen HW; Chou SY; Chen CM; Tsai FJ; Chern Y
Hum Mol Genet; 2009 Aug; 18(16):2929-42. PubMed ID: 19443488
[TBL] [Abstract][Full Text] [Related]
38. Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington's disease.
Chen M; Wolynes PG
Proc Natl Acad Sci U S A; 2017 Apr; 114(17):4406-4411. PubMed ID: 28400517
[TBL] [Abstract][Full Text] [Related]
39. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.
Boussicault L; Alves S; Lamazière A; Planques A; Heck N; Moumné L; Despres G; Bolte S; Hu A; Pagès C; Galvan L; Piguet F; Aubourg P; Cartier N; Caboche J; Betuing S
Brain; 2016 Mar; 139(Pt 3):953-70. PubMed ID: 26912634
[TBL] [Abstract][Full Text] [Related]
40. Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease.
Hunter JM; Lesort M; Johnson GV
J Neurosci Res; 2007 Jun; 85(8):1774-88. PubMed ID: 17455294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
